Funding and Growth Immunai Inc. recently secured substantial funding of $215 million in Series B, indicating a strong financial position and potential for expansion. This financial backing provides an opportunity to scale operations, drive research, and potentially invest in new technologies to enhance offerings.
Strategic Partnerships Immunai Inc. has formed strategic partnerships with industry giants like AstraZeneca plc, showcasing trust in their technology and expertise. Leveraging these partnerships could open doors for collaborative projects, joint ventures, and co-marketing initiatives to create value for both parties and expand reach.
Talent Acquisition With the hiring of Eli Groner, Managing Director at Koch Disruptive Technologies, as a board member, Immunai Inc. shows a commitment to acquiring top talent and industry expertise. Exploiting connections and expertise of board members can lead to networking opportunities, industry insights, and potential introductions to key decision-makers.
Cutting-Edge Technology Immunai Inc. is at the forefront of developing an AI platform that merges big data, single-cell multiomics, and machine learning. This innovative technology differentiates the company in the market and offers a competitive edge, positioning them as a preferred choice for organizations seeking advanced solutions in biotechnology research.
Innovation and Research Immunai Inc.'s dedication to mapping and reprogramming the immune system with single-cell biology and AI showcases a commitment to innovation in healthcare. Adapting to emerging trends, such as personalized medicine and precision therapies, can present avenues for partnerships with organizations looking to pioneer groundbreaking treatments.
93K
$1B
496$50M$100M
582K$1B
474$50M$100M
53$10M
101$10M$50M
73$10M$50M
50$10M
327$50M$100M
1.5K$100M$1BImmunai uses 8 technology products and services including WordPress, Salesforce, MySQL, and more. Explore Immunai's tech stack below.
| Immunai Email Formats | Percentage |
| First.Last@immunai.com | 82% |
| First@immunai.com | 16% |
| First.Middle@immunai.com | 2% |
Biotechnology ResearchNew York, United States51-200 Employees
Comprehensively mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
Company Overview
Media & News
Funding & FinancialsImmunai has raised a total of $215M of funding over 3 rounds. Their latest funding round was raised on Oct 27, 2021 in the amount of $215M.
Immunai's revenue is in the range of $10M$50M
Funding & FinancialsImmunai has raised a total of $215M of funding over 3 rounds. Their latest funding round was raised on Oct 27, 2021 in the amount of $215M.
Immunai's revenue is in the range of $10M$50M
1-888-653-2347 
support@leadiq.com